Forgot Password?
Return to Course Listing

CME: Chronic inflammatory demyelinating polyneuropathy (CIDP): therapeutic updates, best practices, and emerging therapies


Activity Description / Statement of Need:

In this online self-learning program:

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a chronic, acquired, autoimmune disorder affecting the peripheral nervous system. Occurring at an incidence of 4-9 people per 100,000, CIDP most commonly occurs in adults aged of 40 to 60, although it may also occur in children and the elderly. The pathophysiology of CIDP is not completely understood but involves several humoral and cell-mediated mechanisms. Symptoms of CIDP include progressive limb weakness, usually with a predilection for proximal muscles, and sensory loss and are monophasic and progress for 8 weeks or more.

Target Audience:

Healthcare professionals specializing in: neurology, internal medicine; nurse practitioners, physician assistants, nurses, and pharmacists who specialize in neurology; and those who otherwise commonly care for or clinically encounter patients with CIDP.

This program is supported by an educational grant from CSL Behring.

Release Date: January 19, 2018 -- Expiration Date: January 19, 2020

Faculty: Neelam Goyal, MD -- Yuen So, MD, PhD


Faculty introduction, disclosures

Introduction content [Learning Objective #1]

  • Epidemiology
  • Clinical features, presentation, pathophysiology
  • Diagnosis: electrodiagnostic criteria
  • Patient case(s)

Treatment of CIDP [Learning Objectives #2, 3, 4, & 5]

  • Present pharmacotherapy: IVIG, corticosteroids, plasma exchange
  • Literature updates
  • Investigational therapies
  • Clinical pearls
  • Non-pharmacologic treatment
  • Patient case(s)

Summary, conclusions, and best practice recap

Learning Objectives

By the end of the session the participant will be able to:

  • Describe the pathophysiology of CIDP such that it might inform treatment mechanisms
  • Identify the currently available and emerging pharmacotherapeutic treatments for management of CIDP and apply them to patient cases using evidence-based medicine
  • Modify an existing treatment plan for a specific patient with CIDP to optimize safety and efficacy following non-response to therapy
  • Describe non-pharmacological options to manage CIDP



Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.


Faculty Disclosures:


Dr. Neelam Goyal, MD, Clinical Assistant Professor, Stanford Neurosciences Institute, Palo Alto, CA has no relevant financial relationships to disclose.


Dr. Yuen T. So, Associate Chair, Clinical Services, Professor of Neurology, Stanford Neurosciences Institute, Palo Alto, CA has no relevant financial relationships to disclose.


Disclosures of Educational Planners: Charles Turck, PharmDBCPS, BCCCP, CEO of ScientiaCME has no relevant conflicts of interest to disclose.


Commercial Support Disclosure: This program is supported by an educational grant from CSL Behring


  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

System Requirements

Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version

Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.

Additional Courses That Are Related To This Activity

Parkinson's disease: optimizing pharmacotherapeutic management strategies

Parkinson's disease: Highlights from the American Academy of Neurology 2017 Annual Meeting (AAN 2017)

Multiple Sclerosis (MS) and Its Complications: Highlights from the American Academy of Neurology 2016 Annual Meeting (AAN 2016) : Take-Aways, Emerging Practice Changes, and Barriers to their Implementation